Brater D C
Division of Clinical Pharmacology, Indiana University, School of Medicine, Indianapolis.
Eur J Rheumatol Inflamm. 1990;10(1):44-55.
Nonsteroidal anti-inflammatory drugs have been implicated in renal impairment. The purpose of this report is to review the effect of etodolac, a new anti-inflammatory agent, on renal function and the effect of renal impairment on etodolac pharmacokinetics. Pharmacokinetic and renal function studies were conducted in normal and in renally impaired volunteers. Additionally, the renal safety of etodolac was assessed in 2,629 arthritic patients who were treated in clinical trials. The results suggest that etodolac does not affect renal function in normal individuals, nor does it exacerbate underlying renal insufficiency when administered to patients with mild to moderate renal impairment. The pharmacokinetics of etodolac are unchanged in patients on hemodialysis and in elderly patients. Furthermore, no patient was withdrawn from clinical trials for significantly abnormal renal function test values resulting from etodolac therapy alone.
非甾体抗炎药已被认为与肾功能损害有关。本报告的目的是回顾一种新型抗炎药依托度酸对肾功能的影响以及肾功能损害对依托度酸药代动力学的影响。在正常和肾功能受损的志愿者中进行了药代动力学和肾功能研究。此外，在2629例接受临床试验治疗的关节炎患者中评估了依托度酸的肾脏安全性。结果表明，依托度酸对正常个体的肾功能无影响，在给予轻度至中度肾功能损害患者时也不会加重潜在的肾功能不全。依托度酸的药代动力学在接受血液透析的患者和老年患者中未发生改变。此外，没有患者因单纯依托度酸治疗导致肾功能测试值显著异常而退出临床试验。
